Evolving Care for T1D in Pregnancy, with Lois Donovan, MD, and Denise Feig, MD, MSc

An automated insulin delivery (AID) system using Control-IQ Technology allowed women with type 1 diabetes (T1D) in early pregnancy to remain in target blood glucose range for longer than with standard care.1,2

These findings, from an open-label trial, were presented at the 2025 American Diabetes Association (ADA) Scientific Sessions, held June 20-23, in Chicago, Illinois, by endocrinologist Lois Donovan, MD, Clinical Professor, Cumming School of Medicine, and Child Health & Wellness Researcher, Alberta Children's Hospital Research Institute, at University of Calgary.

During the meeting, HCPLive spoke with Donovan as well as the study’s senior investigator, Denice Feig, MD, MSc, Professor of Medicine, University of Toronto, and Head of the Diabetes and Endocrine in Pregnancy Program at Mount Sinai Hospital, to learn more about how T1D care for pregnant women continues to evolve. Feig also serves as an Adjunct Scientist at the Institute for Clinical and Evaluative Sciences, is a Member of the Motherisk Team at SickKids Hospital, and was Past Chair of the Diabetes in Pregnancy Interest Group for the ADA.

Donovan emphasized how far care has come in the last decade and how new research continues to push the envelope. Furthermore, Feig discussed the CONCEPTT trial she investigated in several years ago and how it helped to enable continuous glucose monitoring (CGM) in pregnant people with diabetes, but emphasized that it was a step in the right direction and more work remains to be done to improve outcomes and care.

"We've got some really helpful things that are so much better [for T1D in pregnancy care] than even 8 years ago. And that's what this is all about, making it better for patients to have better outcomes, and making it easier on them," Donovan said.

Donovan’s disclosures include Medtronic, Dexcom, Inc., Tandem Diabetes Care, Inc, and Inner Analytics. Feig’s disclosures include Ypsomed and Novo Nordisk

REFERENCES

1. Donovan LE, Lemieux P, Dunlop A, et al. A Randomized Multicenter Trial of Hybrid Closed-Loop Insulin Therapy with Control-IQ Technology in Type 1 Diabetes in Pregnancy. Presented at ADA 2025; June 20-23; Chicago, Illinois. Poster #2084-LB

2. Smart Insulin Tech Helps Pregnant Women with Type 1 Diabetes Maintain Target Blood Glucose Levels. News release. ADA. June 20, 2025. https://www.prnewswire.com/news-releases/smart-insulin-tech-helps-pregnant-women-with-type-1-diabetes-maintain-target-blood-glucose-levels-302487332.html